

Jason S Carroll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8925131/publications.pdf>

Version: 2024-02-01

144
papers

21,285
citations

15504

65
h-index

10445

139
g-index

169
all docs

169
docs citations

169
times ranked

27502
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. <i>Nature</i> , 2012, 481, 389-393.	27.8	1,655
2	Pioneer transcription factors: establishing competence for gene expression. <i>Genes and Development</i> , 2011, 25, 2227-2241.	5.9	1,388
3	Genome-wide analysis of estrogen receptor binding sites. <i>Nature Genetics</i> , 2006, 38, 1289-1297.	21.4	1,227
4	Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1. <i>Cell</i> , 2005, 122, 33-43.	28.9	1,208
5	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
6	FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription. <i>Cell</i> , 2008, 132, 958-970.	28.9	863
7	Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. <i>Cell</i> , 2009, 138, 245-256.	28.9	797
8	FOXA1 is a key determinant of estrogen receptor function and endocrine response. <i>Nature Genetics</i> , 2011, 43, 27-33.	21.4	722
9	A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer Growth. <i>Molecular Cell</i> , 2007, 27, 380-392.	9.7	598
10	Progesterone receptor modulates ER α action in breast cancer. <i>Nature</i> , 2015, 523, 313-317.	27.8	504
11	Spatial and Temporal Recruitment of Androgen Receptor and Its Coactivators Involves Chromosomal Looping and Polymerase Tracking. <i>Molecular Cell</i> , 2005, 19, 631-642.	9.7	401
12	Model-based analysis of tiling-arrays for ChIP-chip. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12457-12462.	7.1	390
13	p63 regulates an adhesion programme and cell survival in epithelial cells. <i>Nature Cell Biology</i> , 2006, 8, 551-561.	10.3	372
14	Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4260-4265.	7.1	366
15	A CTCF-independent role for cohesin in tissue-specific transcription. <i>Genome Research</i> , 2010, 20, 578-588.	5.5	331
16	Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor. <i>Cell Reports</i> , 2013, 3, 342-349.	6.4	319
17	Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer. <i>Cancer Research</i> , 2007, 67, 6477-6483.	0.9	317
18	Estradiol-regulated microRNAs control estradiol response in breast cancer cells. <i>Nucleic Acids Research</i> , 2009, 37, 4850-4861.	14.5	310

#	ARTICLE	IF	CITATIONS
19	GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. <i>Genome Research</i> , 2013, 23, 12-22.	5.5	307
20	Regulation of ERBB2 by oestrogen receptor- α PAX2 determines response to tamoxifen. <i>Nature</i> , 2008, 456, 663-666.	27.8	283
21	Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. <i>EMBO Journal</i> , 2008, 27, 535-545.	7.8	279
22	A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. <i>Genes and Development</i> , 2006, 20, 2513-2526.	5.9	261
23	Estrogen Receptor Target Gene: An Evolving Concept. <i>Molecular Endocrinology</i> , 2006, 20, 1707-1714.	3.7	249
24	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , 2011, 30, 3019-3027.	7.8	247
25	Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. <i>Nature Protocols</i> , 2016, 11, 316-326.	12.0	235
26	Pioneer factors in hormone-dependent cancers. <i>Nature Reviews Cancer</i> , 2012, 12, 381-385.	28.4	233
27	Cooperative interaction between retinoic acid receptor- α and estrogen receptor in breast cancer. <i>Genes and Development</i> , 2010, 24, 171-182.	5.9	227
28	Site-selective modification strategies in antibody-drug conjugates. <i>Chemical Society Reviews</i> , 2021, 50, 1305-1353.	38.1	207
29	Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. <i>Nature Reviews Cancer</i> , 2007, 7, 713-722.	28.4	191
30	Growth factor stimulation induces a distinct ER α cistrome underlying breast cancer endocrine resistance. <i>Genes and Development</i> , 2010, 24, 2219-2227.	5.9	156
31	IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. <i>Cancer Cell</i> , 2020, 38, 412-423.e9.	16.8	145
32	A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression. <i>PLoS Genetics</i> , 2011, 7, e1002165.	3.5	142
33	Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3787-3792.	7.1	129
34	A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence. <i>Journal of Biological Chemistry</i> , 2000, 275, 38221-38229.	3.4	126
35	FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3. <i>Cell Reports</i> , 2016, 17, 2715-2723.	6.4	122
36	The androgen receptor is a tumor suppressor in estrogen receptor- α positive breast cancer. <i>Nature Medicine</i> , 2021, 27, 310-320.	30.7	122

#	ARTICLE	IF	CITATIONS
37	A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 37-47.	2.5	121
38	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
39	Unique ER \pm Cistromes Control Cell Type-Specific Gene Regulation. <i>Molecular Endocrinology</i> , 2008, 22, 2393-2406.	3.7	119
40	<i>ZNF703</i> is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. <i>EMBO Molecular Medicine</i> , 2011, 3, 167-180.	6.9	119
41	Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor α -positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 908-920.	4.1	119
42	Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. <i>Genome Research</i> , 2008, 18, 393-403.	5.5	117
43	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. <i>Molecular Cell</i> , 2020, 78, 1096-1113.e8.	9.7	114
44	Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. <i>Genome Biology</i> , 2013, 14, R6.	9.6	113
45	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. <i>Nature Communications</i> , 2017, 8, 1865.	12.8	108
46	ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. <i>Nature Genetics</i> , 2020, 52, 187-197.	21.4	108
47	Signaling pathways and steroid receptors modulating estrogen receptor \pm function in breast cancer. <i>Genes and Development</i> , 2018, 32, 1141-1154.	5.9	107
48	Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. <i>Molecular and Cellular Endocrinology</i> , 2005, 229, 161-173.	3.2	106
49	Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. <i>EMBO Journal</i> , 2011, 30, 4764-4776.	7.8	105
50	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	12.8	105
51	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. <i>Cell Reports</i> , 2015, 13, 108-121.	6.4	105
52	A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. <i>Nature Communications</i> , 2018, 9, 2311.	12.8	104
53	Deciphering the divergent roles of progestogens in breast cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 54-64.	28.4	96
54	A patient α -derived explant (α PDE α) model of hormone α -dependent cancer. <i>Molecular Oncology</i> , 2018, 12, 1608-1622.	4.6	94

#	ARTICLE	IF	CITATIONS
55	Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. <i>Molecular and Cellular Endocrinology</i> , 2017, 440, 138-150.	3.2	91
56	AKT Alters Genome-Wide Estrogen Receptor β Binding and Impacts Estrogen Signaling in Breast Cancer. <i>Molecular and Cellular Biology</i> , 2008, 28, 7487-7503.	2.3	87
57	Estrogen receptor beta in prostate cancer: friend or foe?. <i>Endocrine-Related Cancer</i> , 2014, 21, T219-T234.	3.1	85
58	A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates. <i>Chemical Science</i> , 2019, 10, 694-700.	7.4	85
59	Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4482-E4491.	7.1	83
60	Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 3417-3430.	0.9	79
61	Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. <i>Cancer Research</i> , 2002, 62, 6916-23.	0.9	79
62	Development of an Illumina-based ChIP-exonuclease method provides insight into FoxA1-DNA binding properties. <i>Genome Biology</i> , 2013, 14, R147.	9.6	76
63	FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 3680-3689.	7.0	75
64	ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. <i>PLoS Biology</i> , 2012, 10, e1001461.	5.6	74
65	FoxA1 is a Key Mediator of Hormonal Response in Breast and Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 68.	3.5	73
66	The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 385-396.	2.5	70
67	The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex. <i>Nucleic Acids Research</i> , 2014, 42, 6232-6242.	14.5	66
68	ERR β induces H3K9 demethylation by LSD1 to promote cell invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3909-3914.	7.1	66
69	Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc. <i>Molecular and Cellular Biology</i> , 2009, 29, 4623-4639.	2.3	61
70	Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. <i>Cancer Research</i> , 2002, 62, 3126-31.	0.9	61
71	Runx2 Is a Novel Regulator of Mammary Epithelial Cell Fate in Development and Breast Cancer. <i>Cancer Research</i> , 2014, 74, 5277-5286.	0.9	60
72	A co-ordinated interaction between CTCF and ER in breast cancer cells. <i>BMC Genomics</i> , 2011, 12, 593.	2.8	58

#	ARTICLE	IF	CITATIONS
73	A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. <i>BMC Genomics</i> , 2013, 14, 232.	2.8	54
74	FOXA1 mutations in hormone-dependent cancers. <i>Frontiers in Oncology</i> , 2013, 3, 20.	2.8	50
75	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17. <i>Cancer Research</i> , 2016, 76, 5881-5893.	0.9	50
76	Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice. <i>ELife</i> , 2017, 6, .	6.0	50
77	Co-regulated gene expression by oestrogen receptor $\hat{\pm}$ and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. <i>Nucleic Acids Research</i> , 2013, 41, 10228-10240.	14.5	49
78	Comprehensive Genomic Analysis Reveals that the Pioneering Function of FOXA1 Is Independent of Hormonal Signaling. <i>Cell Reports</i> , 2019, 26, 2558-2565.e3.	6.4	49
79	Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2748-2753.	7.1	47
80	ER $\hat{2}$ -mediated induction of cystatins results in suppression of TGF $\hat{2}$ signaling and inhibition of triple-negative breast cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9580-E9589.	7.1	47
81	<i>EN1</i> Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis. <i>Cancer Research</i> , 2019, 79, 4173-4183.	0.9	47
82	Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. <i>American Journal of Pathology</i> , 2010, 176, 2139-2149.	3.8	40
83	Tamoxifen-Induced Apoptosis of MCF-7 Cells via GPR30/PI3K/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing. <i>Frontiers in Physiology</i> , 2018, 9, 907.	2.8	40
84	Sulfatase-cleavable linkers for antibody-drug conjugates. <i>Chemical Science</i> , 2020, 11, 2375-2380.	7.4	40
85	Nlx3-1 and LEF-1 Function as Transcriptional Inhibitors of Estrogen Receptor Activity. <i>Cancer Research</i> , 2008, 68, 7380-7385.	0.9	39
86	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv371.	6.3	37
87	High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53 - NF-kappaB - complex-dependent gene expression in human heart failure. <i>Genome Medicine</i> , 2010, 2, 37.	8.2	32
88	p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. <i>Cancer Research</i> , 2003, 63, 4322-6.	0.9	31
89	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. <i>Cancer Research</i> , 2022, 82, 1321-1339.	0.9	30
90	Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer. <i>Journal of Immunology</i> , 2019, 202, 3076-3086.	0.8	29

#	ARTICLE	IF	CITATIONS
91	Complex Formation and Function of Estrogen Receptor $\hat{\pm}$ in Transcription Requires RIP140. <i>Cancer Research</i> , 2014, 74, 5469-5479.	0.9	28
92	Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. <i>Nucleic Acids Research</i> , 2018, 46, 11214-11228.	14.5	28
93	Genome-Wide Estrogen Receptor Activity in Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	2.8	28
94	A Low Abundance Pool of Nascent p21 ^{WAF1/Cip1} Is Targeted by Estrogen to Activate Cyclin E $\hat{\Delta}$ -Cdk2. <i>Journal of Biological Chemistry</i> , 2001, 276, 45433-45442.	3.4	26
95	FOXA1 and breast cancer risk. <i>Nature Genetics</i> , 2012, 44, 1176-1177.	21.4	26
96	Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing. <i>BMC Medical Genomics</i> , 2013, 6, 21.	1.5	25
97	Estrogen receptor $\hat{\Delta}$ -positive breast cancer: a multidisciplinary challenge. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2011, 3, 216-230.	6.6	24
98	Transcription factors and chromatin proteins as therapeutic targets in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 183-192.	7.4	24
99	The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. <i>Nature</i> , 2022, 606, 999-1006.	27.8	24
100	Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. <i>Oncogene</i> , 2018, 37, 2008-2021.	5.9	23
101	The logic of transcriptional regulator recruitment architecture at <i>cis</i> -regulatory modules controlling liver functions. <i>Genome Research</i> , 2017, 27, 985-996.	5.5	22
102	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 295-309.	2.5	21
103	TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor <i>cis</i> -regulatory regions. <i>Cell Reports</i> , 2021, 34, 108776.	6.4	20
104	xMAN: extreme MAPPING of OligoNucleotides. <i>BMC Genomics</i> , 2008, 9, S20.	2.8	19
105	General dual functionalisation of biomacromolecules <i>via</i> a cysteine bridging strategy. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 4224-4230.	2.8	19
106	ELF5 modulates the estrogen receptor <i>cis</i> trome in breast cancer. <i>PLoS Genetics</i> , 2020, 16, e1008531.	3.5	17
107	A dual-enzyme cleavable linker for antibody $\hat{\Delta}$ -drug conjugates. <i>Chemical Communications</i> , 2021, 57, 3457-3460.	4.1	16
108	Chromatin Immunoprecipitation-Sequencing (ChIP-seq) for Mapping of Estrogen Receptor-Chromatin Interactions in Breast Cancer. <i>Methods in Molecular Biology</i> , 2016, 1366, 79-98.	0.9	16

#	ARTICLE	IF	CITATIONS
109	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. <i>Nature Communications</i> , 2021, 12, 6377.	12.8	16
110	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. <i>Oncogene</i> , 2019, 38, 1136-1150.	5.9	15
111	Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia. <i>Cell Reports</i> , 2021, 36, 109725.	6.4	15
112	Elevated ASCL1 activity creates de novo regulatory elements associated with neuronal differentiation. <i>BMC Genomics</i> , 2022, 23, 255.	2.8	15
113	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 479-491.	7.0	14
114	Dephosphorylation of the Proneural Transcription Factor ASCL1 Re-Engages a Latent Post-Mitotic Differentiation Program in Neuroblastoma. <i>Molecular Cancer Research</i> , 2020, 18, 1759-1766.	3.4	14
115	Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 126.	5.0	14
116	Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 23045-23050.	13.8	14
117	Rapid and robust cysteine bioconjugation with vinylheteroarenes. <i>Chemical Science</i> , 2021, 12, 9060-9068.	7.4	14
118	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. <i>Oncogene</i> , 2020, 39, 5455-5467.	5.9	12
119	ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis. <i>Leukemia</i> , 2022, 36, 549-554.	7.2	11
120	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. <i>Oncogene</i> , 2021, 40, 1318-1331.	5.9	10
121	Divinylpyrimidine reagents generate antibody drug conjugates with excellent <i>in vivo</i> efficacy and tolerability. <i>Chemical Communications</i> , 2022, 58, 1962-1965.	4.1	10
122	Interrogating the genome to understand oestrogen-receptor-mediated transcription. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e10.	3.9	9
123	Estrogen receptor action in three dimensions - looping the loop. <i>Breast Cancer Research</i> , 2010, 12, 303.	5.0	9
124	Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha. <i>PLoS ONE</i> , 2019, 14, e0215340.	2.5	9
125	Analysis of HER2 genomic binding in breast cancer cells identifies a global role in direct gene regulation. <i>PLoS ONE</i> , 2019, 14, e0225180.	2.5	9
126	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p65 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	5.2	9

#	ARTICLE	IF	CITATIONS
127	Approaches for Assessing and Discovering Protein Interactions in Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 1295-1302.	3.4	7
128	RIME proteomics of estrogen and progesterone receptors in breast cancer. <i>Data in Brief</i> , 2015, 5, 276-280.	1.0	7
129	Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 47.	17.0	7
130	ChIPing away at breast cancer. <i>Lancet Oncology</i> , The, 2012, 13, 1185-1187.	10.7	5
131	Enhancer-derived RNAs: "spicing up" transcription programs. <i>EMBO Journal</i> , 2013, 32, 2096-2098.	7.8	3
132	Preface. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 623.	3.2	3
133	The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen. <i>Oncogene</i> , 2020, 39, 6300-6312.	5.9	3
134	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , 2012, 31, 1617-1617.	7.8	2
135	Targeting LSD1 and FOXA1 in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1002-1003.	21.4	2
136	ncRNAseq: simple modifications to RNA-seq library preparation allow recovery and analysis of mid-sized non-coding RNAs. <i>BioTechniques</i> , 2022, 72, 21-28.	1.8	2
137	An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0151785.	2.5	1
138	Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. <i>Angewandte Chemie</i> , 2020, 132, 23245-23250.	2.0	0
139	Estrogen/Estrogen Antagonist Regulation of the Cell Cycle in Breast Cancer Cells. , 2002, , 57-71.		0
140	Antiestrogens and the Cell Cycle. , 2009, , 17-45.		0
141	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0
142	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0
143	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0
144	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0